![](https://www.nemera.net/wp-content/uploads/2021/06/POST-8.png)
The pivotal role played by device developers to improve patient eye care
05/06/2021
Novelia, our preservative-free multidose eye dropper, that addresses the challenges of patients suffering from glaucoma & dry eye diseases.
Continue Reading05/06/2021
Novelia, our preservative-free multidose eye dropper, that addresses the challenges of patients suffering from glaucoma & dry eye diseases.
Continue Reading05/06/2021
At Nemera, we strive to offer solutions to prevent overdosing of potent drugs.
Continue Reading05/06/2021
The untold story of Nemera’s inhalation franchise Introduction and disease overview: Imagine the sheer joy and excitement of a child running towards an ice cream truck on a hot ...
Continue Reading28/05/2021
Considerations for device selection in parenteral applications. Mark Tunkel, Global Category Director, Services at Nemera, looks at the challenges involved in the selection of drug devices for combination products and...
Continue Reading04/05/2021
In this report, Alira Health in partnership with MassMEDIC analyzes the rapidly evolving DDD landscape and how industry leaders like Nemera strive to enhance the end-to-end services offering by integrating...
Continue Reading27/05/2021
Developing inhalation devices with the patients, from early-stage to validation Treating chronic respiratory diseases: a challenge for both patients and pharma providers. Living with chronic respiratory diseases like Asthma ans...
Continue Reading